Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing.
about
Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathwayAdipose tissue NAD+ biology in obesity and insulin resistance: From mechanism to therapyPersonal model-assisted identification of NAD+ and glutathione metabolism as intervention target in NAFLD.Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway.The role of caloric load and mitochondrial homeostasis in the regulation of the NLRP3 inflammasome.Emerging roles of SIRT1 in fatty liver diseases.NAD replenishment with nicotinamide mononucleotide protects blood-brain barrier integrity and attenuates delayed tissue plasminogen activator-induced haemorrhagic transformation after cerebral ischaemia.Reply to Moon and Minhas: Teasing apart NAD+ metabolism in inflammation: commentary on Zhou et al. (2016). Br J Pharmacol 173: 2352-2368.NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR.Nicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice.Targeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule.The Emergence of the Nicotinamide Riboside Kinases in the regulation of NAD+ Metabolism.Teasing apart NAD+ metabolism in inflammation: commentary on Zhou et al. (2016). Br J Pharmacol 173: 2352-2368.
P2860
Q33612522-2D645C6F-D0B1-44A0-A920-1D4A96A26890Q33791807-B5AF6925-8972-4F5B-A86F-3DEE629315B4Q37727707-258AC3F2-5BE9-44C5-8DD4-1D3B8C23B89AQ38720863-4870B537-4E9E-44D1-AB98-6750F49D9C31Q39036066-3DC28946-B4EB-4619-81C1-BD6C39B16C08Q41377073-CFB6F3E5-44EE-44E9-A845-FB2F679E19C7Q47947055-43DE7751-3A3C-497C-A06E-C38F13886750Q48323498-041AC542-A5EF-458B-BA25-0E0EEFBD632DQ49712935-6C70125C-B2BA-416F-B173-7EDED4E12ED3Q51765157-4C7A49CB-0C38-485E-A6F1-7C15AD5DEDD2Q51776565-DD378737-B129-47C8-B372-C8546115C7DFQ54977650-6AC5231E-2E82-4A1C-A696-AC73ECAC63CCQ55191018-0F6E4FEF-30ED-4726-B53D-88C28FC624DB
P2860
Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Hepatic NAD(+) deficiency as a ...... fatty liver disease in ageing.
@en
type
label
Hepatic NAD(+) deficiency as a ...... fatty liver disease in ageing.
@en
prefLabel
Hepatic NAD(+) deficiency as a ...... fatty liver disease in ageing.
@en
P2093
P2860
P356
P1476
Hepatic NAD(+) deficiency as a ...... fatty liver disease in ageing
@en
P2093
Can-Can Zhou
Guo-Qiang Li
Mao-Bing Fan
Tian-Ying Xu
Yun-Feng Guan
Zhi-Yong Li
P2860
P304
P356
10.1111/BPH.13513
P407
P577
2016-06-27T00:00:00Z